Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview
Colorectal cancer (CRC) is one of the most common malignancies worldwide, with high morbidity and mortality rates. Conventional treatments, including surgery, radiotherapy, and chemotherapy, have limited effects on advanced and metastatic CRC (mCRC). Fruquintinib, a novel and highly selective vascul...
Saved in:
| Main Authors: | Yejie Xie, Shu Tang, Ziheng Qin, Chaogang Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/2/280 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial
by: Weibing Leng, et al.
Published: (2025-02-01) -
Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway
by: Qinqin Song, et al.
Published: (2025-03-01) -
The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study
by: Yao Wang, et al.
Published: (2025-07-01) -
Correction: The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study
by: Frontiers Production Office
Published: (2025-08-01) -
Effect of prognostic nutritional index on laboratory parameters and survival in metastatic colorectal cancer patients treated with fruquintinib: a retrospective study
by: Zeng Wang, et al.
Published: (2024-11-01)